Barnes Jewish Hospital in St Louis is the tenth transplant center to participate in the Swedish medtech company Xvivo’s NOVEL trial.
The NOVEL trial is designed to evaluate the effect of the product Steen Solutions in increasing the amount of usable lungs in the donor pool. The study is being performed at 10 centers in the United States. In the study, clinical outcomes after transplantation of lungs that have undergone warm perfusion after having been initially discarded are compared with a control group of lungs – non marginal – consisting of lungs that were initially assessed as non-transplantable.
“We are pleased that another well-known center has joined the NOVEL trial and that the connected OPO has invested in a XPS™. This collaboration is second of its kind in the US and will increase the utilization of lungs and give transplants to more patients with severe lung disease ” says Dr. Magnus Nilsson CEO of XVIVO Perfusion, in a press release.